Given the different subunits and substrates of the two mTOR complexes, it is increasingly recognized that these complexes are distinct in their physiological roles and have different consequences to their activation and dysregulation in cancer (Morrison Joly et al., 2016). This evidence concerns the gene MTOR and cancer.